PMGC Holdings Inc.

What they do

PMGC Holdings operates a portfolio of wholly owned subsidiaries across several sectors. NorthStrive Biosciences is developing EL-22, an engineered probiotic candidate intended to preserve muscle during GLP-1 weight-loss treatment, which has completed a Phase 1 trial in South Korea. Pacific Sun Packaging supplies custom protective packaging for components such as CPUs, DIMMs, SSDs and HDDs. AGA Precision Systems and A&B Aerospace run CNC machining and precision component operations serving aerospace, defense and industrial customers. PMGC Capital makes direct investments and strategic loans, and the company has sold its prior Elevai Skincare business.

Revenue drivers

• Precision manufacturing and packaging subsidiaries — Pacific Sun Packaging, AGA Precision Systems, SVM Machining and A&B Aerospace generate revenue from custom-engineered packaging and high-tolerance machined components for electronics, aerospace, defense and industrial customers; these operating businesses appear to account for the bulk of reported revenue.
• NorthStrive Biosciences (EL-22) — The biopharmaceutical segment is development-stage and has no approved product revenue; EL-22 has completed only a Phase 1 safety trial in healthy volunteers in South Korea.
• PMGC Capital — A multi-strategy investment subsidiary focused on direct investments, strategic lending and acquiring undervalued companies and assets, positioned as a returns-on-capital activity rather than an operating revenue line.
• ELAB Opportunity Holdings / NorthStrive Defense Tech — ELAB Opportunity Holdings holds assets related to secured pre-paid purchase and financing collateral arrangements, and NorthStrive Defense Tech was formed to identify, acquire and commercialize defense technologies including drones and autonomous systems.

Recent performance

Recent quarterly revenue has been uneven: $527,478 for the quarter ended 2024-09-30 fell to $285,948 for the quarter ended 2025-09-30, then rose to $681,994 for the quarter ended 2026-03-31 and $1.3M for the quarter ended 2026-06-30. Full-year revenue was $1.7M in 2023 but $590,084 in 2025, while net losses widened from $4.3M in 2023 to $6.2M in 2024 and $7.7M in 2025. Operating cash use increased from $4.6M in 2023 to $5.9M in 2025. As of 2026-06-30, total assets were $36.6M, total liabilities $19.8M, shareholder equity $16.7M and cash and equivalents $18.1M.

Strategy

Management describes PMGC Holdings as a diversified holding company that acquires and grows operating businesses and biotechnology assets, and has been adding manufacturing and aerospace subsidiaries including SVM Machining, A&B Aerospace and the Indarg Engineering assets. The January 2025 divestiture of the Elevai Skincare assets redirected resources toward NorthStrive Biosciences and larger-market opportunities. AGA Precision Systems merged into A&B Aerospace on July 2, 2026, with A&B surviving. Stated priorities include advancing EL-22 in combination with weight-loss therapeutics and continuing acquisitions, funded by operations and debt or equity sales.

Risks

• Going concern — The 10-K states the company's financial statements are prepared on a going-concern basis and that continued operations are in doubt, based on recurring losses, limited revenue and limited working capital.
• Cash burn exceeds revenue — Operating cash use was $5.9M in 2025 while full-year revenue was $590,084, and management states it depends on obtaining funding from operations and debt or equity sales.
• Accumulated deficit and widening losses — Accumulated deficit was $21,017,440 at December 31, 2025, up from $13,269,627 a year earlier, with net losses of $7,747,813 in 2025 and $6,245,737 in 2024.
• Holding company and acquisition complexity — The 10-K warns that the company may not realize benefits from managing multiple subsidiaries under one structure and that subsidiaries may operate with limited synergies while adding overhead, compliance and management costs.

Outlook

Management states that the company intends to evaluate EL-22 for efficacy and safety in combination with weight-loss therapeutics, seeking to reduce fat mass while preventing muscle wasting. It says it will continue pursuing acquisitions of operating companies and biotechnology assets to strengthen the portfolio. The 10-K says that without additional funding the company may have to delay, reduce or eliminate planned operations, including research and development and clinical validation studies.